Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 23;11(9):1035.
doi: 10.3390/children11091035.

Assessment of the Circulating PD-1 and PD-L1 Levels and P53 Expression as a Predictor of Relapse in Pediatric Patients with Wilms Tumor and Hypernephroma

Heba A Sahyon  1 , Nadaa S Alharbi  2   3 , Zummar Asad  2 , Mohamed A El Shishtawy  4 , Safaa A Derbala  5
Affiliations

Assessment of the Circulating PD-1 and PD-L1 Levels and P53 Expression as a Predictor of Relapse in Pediatric Patients with Wilms Tumor and Hypernephroma

Heba A Sahyon et al. Children (Basel). .

Abstract

Background/Objectives: Wilms tumor (WT) is the most common form of pediatric renal tumor, accounting for over 90% of cases followed by hypernephroma. Some pediatric patients with WT (10%) experience relapse or metastasis and have poor survival rates. PD-L1 assists cancer cells in escaping damage from the immune system. P53 mutations are found in relapsed WT tumor samples. We hypothesized that testing circulating PD-1 and PD-L1 and P53 expression levels could offer a simple method to predict patient relapse and explore novel treatments for pediatric WTs and hypernephroma. Methods: Flow cytometric detection of cPD-1, cPD-L1, and P53 expression in relapsed and in-remission WT and hypernephroma before and after one year of chemotherapy was performed. Results: Our data shows increased levels of cPD-L1 in relapsed pediatric patients with WT or hypernephroma before and after chemotherapy. There were also slight and significant increases in cPD-1 levels in relapsed groups before chemotherapy. Additionally, we observed significant decreases in P53 expression after one year of chemotherapy in relapsed pediatric patients. Conclusions: Our study found that circulating PD-L1 can be used as a predictor marker for WT and hypernephroma relapse. In conclusion, these circulating markers can assist in monitoring relapse in WT and hypernephroma patients without the need for several biopsies.

Keywords: P53; PD-1; PD-L1; Wilms tumor; hypernephroma; pediatric renal tumor; relapse.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Circulating PD-1, PD-L1, and P53 expression levels before and after one year of chemotherapy between in-remission and relapse groups. # p ≤ 0.05 represents a significant difference compared to relapsed group.
Figure 2
Figure 2
Circulating PD-1 and PD-L1 levels in relapsed and in-remission study groups before and after one year of chemotherapy.
Figure 3
Figure 3
Circulating PD-1, PD-L1, and P53 expression correlations to kidney tumor stage in WT (A,C,E) and hypernephroma (B,D,F) groups.
Figure 4
Figure 4
P53 expression levels in relapsed and in-remission study groups before and after one year of chemotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Carter N., Avery A., Libes J., Lovvorn H., Hansen E. Pediatric Solid Tumors in Resource-Constrained Settings: A Review of Available Evidence on Management, Outcomes, and Barriers to Care. Children. 2018;5:143. doi: 10.3390/children5110143. - DOI - PMC - PubMed
    1. Pater L., Melchior P., Rübe C., Cooper B.T., McAleer M.F., Kalapurakal J.A., Paulino A.C. Wilms Tumor. Pediatr. Blood Cancer. 2021;68:e28257. doi: 10.1002/pbc.28257. - DOI - PubMed
    1. Groenendijk A., Spreafico F., de Krijger R.R., Drost J., Brok J., Perotti D., van Tinteren H., Venkatramani R., Godziński J., Rübe C., et al. Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature. Cancers. 2021;13:3142. doi: 10.3390/cancers13133142. - DOI - PMC - PubMed
    1. Zhang L.-J., Liu W., Gao Y.-M., Qin Y.-J., Wu R.-D. The Expression of IL-6 and STAT3 Might Predict Progression and Unfavorable Prognosis in Wilms’ Tumor. Biochem. Biophys. Res. Commun. 2013;435:408–413. doi: 10.1016/j.bbrc.2013.04.102. - DOI - PubMed
    1. Liu W., Zhang L., Wu R. Differential Expression of STAT1 and IFN-γ in Primary and Invasive or Metastatic Wilms Tumors. J. Surg. Oncol. 2013;108:152–156. doi: 10.1002/jso.23364. - DOI - PubMed

LinkOut - more resources